Mantle cell lymphoma

Active Research Protocols

  1. 00-C-0133 – Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma
  2. 01-H-0162 – Ex Vivo Selective Depletion of Alloreactive Donor T-Lymphocytes Using RFT5-SMPT-dgA, a Specific Anti-Interleukin-2 Receptor Immunotoxin: Reducing GVHD Risk Associated with HLA-Matched, Nonmyeloablative, Peripheral Blood Stem Cell Transplantation for Hemat
  3. 05-C-0170 – Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib (EPOCH-R-B) Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma with Microarray Profiling and Proteomics
  4. 07-C-0081 – A Phase I/II Study of Flavopiridol in Relapsed or Refractory Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
  5. 09-C-0082 – Assessment of the Safety and Feasibility of Administering T cells Expressing an anti-CD19 Chimeric Antigen Receptor to Patients with B-cell Lymphoma or Leukemia
  6. 09-H-0094 – A Pilot Study of the Safety and Efficacy of Escalating Doses of ON 01910.Na in Patients with Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
  7. 10-C-0067 – A Phase 1-2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
  8. 10-H-0097 – A Study of the Kinetics of Lymphoid Cells in Patients with Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers.
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014